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ff-Label Use
f Drug-Eluting Stents
utting it in Perspective*
indy L. Grines, MD, FACC
oyal Oak, Michigan
ince Food and Drug Administration (FDA) approval of
he first drug-eluting stent (DES) in April 2003, their use
ncreased to 90% of all coronary stent procedures in the U.S.
y 2006 (1). With restenosis virtually eliminated, DES were
pplied to increasingly more complex coronary lesions.
owever, over the past few years, reports of late stent
hrombosis began to emerge. Additional reports of late stent
hrombosis and increased mortality compared with bare-
etal stents (BMS) emerged from the European Society of
ardiology meeting in the fall of 2006 (2). These reports
ere eventually thought to be not entirely accurate owing to
ncomplete data and the methods of analysis. However,
edia attention, litigation concerns, and physician confu-
ion resulted in a remarkable 42% decrease in the sales of
ES over the next 6 months (3). Was the cardiology
ommunity overreacting, or was this drop in utilization of
ES justified?
See page 607
he FDA Process
o address these concerns, the FDA convened the Circu-
atory System Devices Advisory Panel on December 7 and
, 2006, to fully characterize the risk of DES thrombosis
4). They concluded that, compared with BMS, both types
f FDA-approved DES (Cypher [Cordis, Miami Lakes,
lorida] and Taxus [Boston Scientific, Natick, Massachu-
etts]) are associated with a small increase in stent throm-
osis that emerges 1 year after stent implantation. However,
his was not associated with an increased risk of death and
I (possibly owing to insufficient numbers or being offset
y a reduction in events from prevention of restenosis and
dditional revascularization procedures). They concluded
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the William Beaumont Hospital, Royal Oak, Michigan. Dr. Grines receivesc
onsulting fees from CV Therapeutics and has contracted research for Aventis, Cardium
herapeutics, Cardiovascular Research Foundation, and Takeda Pharmaceuticals.hat concerns about thrombosis do not outweigh the bene-
ts of DES when implanted for approved indication.
The FDA panel also observed that at least 60% of current
ES use is off-label, and off-label use is associated with
ncreased events. However, they acknowledge that “with
ore complex patients there is an expected increased risk in
dverse events” and noted that the FDA does “not regulate
ow [DES] are used by individual clinicians in the practice
f medicine” (4).
Although some have accused our regulatory agency of
eing too lenient, the FDA approval process is thought to
e more arduous, expensive, and delayed than in most other
ountries (5). Even after initial FDA approval, expanding
he approved indications is costly and requires 4 or more
ears of work (6). Some have estimated that excessive delays
n FDA approval may have resulted in death in hundreds of
housands of patients and morbidity in millions of Ameri-
ans (5).
Although the current controversy surrounds off-label use
f DES, even balloons and BMS have very limited indica-
ions (7). Moreover, aspirin, unfractionated heparin, and
lopidogrel are not FDA approved for routine elective
ercutaneous coronary intervention (PCI). Clearly, an in-
erventional cardiologist would not omit these important
ntithrombotic agents even though they are not FDA
pproved for PCI. Likewise, physicians must use their
linical judgment in deciding the best device to use in the
oronary artery. In fact, FDA guidelines acknowledge that
good medical practice and the best interests of the patient
equire that physicians use legally available drugs, biologics,
nd devices according to their best knowledge and judgment
6–8)” and does not confine the use to FDA-approved
ndications.
ES: Outcomes With Off-Label
ompared With FDA-Approved Indications
n several clinical series, off-label use occurred in nearly 60%
f patients undergoing DES. These patients are a high-risk
opulation with numerous comorbidities, unfavorable lesion
orphology and unstable clinical presentations. Similar to
MS use for off-label indications, the results obtained with
ES were generally less favorable than in patients treated
or “on-label” indications.
Beohar et al. (9) reported a multicenter registry in which
,541 patients received DES, of which 47% were for
ff-label or untested indications. The 30-day risk of death,
yocardial infarction (MI), or stent thrombosis and 1-year
ate of target vessel revascularization (TVR) was signifi-
antly higher when DES were used off-label compared with
pproved indications; however, absolute event rates were
uite low. Win et al. (10) reported a multicenter registry of
,323 patients treated with DES, of whom 55% had at least
off-label indication. They noted similar mortality but a
igher risk of MI, stent thrombosis, and TVR in off-label
ompared with FDA-approved DES indications.
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Editorial Comment February 12, 2008:615–7Rao et al. (11) reported the largest series: 408,033
rocedures using DES in the National Cardiovascular Data
egistry. When DES were used for off-label indications
acute MI, in-stent restenosis, bypass grafts, chronic total
cclusions), the rates of in-hospital events were actually
ower than expected from a validated model. These data
uggest that case selection and physician decision making
egarding use of DES for off-label indications appears to be
afe and appropriate.
ES Compared With BMS for Off-Label Indications
n this issue of the Journal, Applegate et al (12) report their
ingle-center observational study of 1,164 consecutive pa-
ients treated with BMS (before availability of DES) and
,285 consecutive patients treated with DES. Stents were
sed for off-label indications in 75% of BMS and 80% of
ES, attesting to the complexity of some cardiology prac-
ices. As expected, off-label use of either stent type was
ssociated with worse outcomes at 2 years than on-label
pplications. However, for high-risk off-label indications,
ES was superior to BMS at reducing death (hazard ratio
HR] 0.72) and the combined end point of death or
onfatal MI (HR 0.78). Limitations of this study include
he lack of randomization, the fact that the BMS group was
istorical, changes in pharmacotherapy over time, and that
he study was underpowered to determine stent thrombosis.
owever, better clinical outcomes with DES and no in-
rease in stent thrombosis at 2 years should be reassuring to
he interventional cardiology community.
Although randomized trials of off-label DES versus BMS
ave not yet been reported, numerous registries and ran-
omized trials suggest that DES are safe and effective in
ubsets of patients and lesions that were not tested in the
ivotal trials (13,14). Over the past year, several prospective
andomized trials demonstrated improved angiographic and
linical outcomes comparing DES with BMS in complex
esion subsets (15), long lesions requiring overlapped stents
16), in-stent restenosis (17–19), saphenous vein grafts (20),
hronic total occlusions (21), and 8 different primary PCI
rials (22).
Because off-label use of both BMS and DES is wide-
pread, one may look to large population registries to
etermine safety. Although the original SCAAR (Swedish
oronary Angiography and Angiolasty Registry) publica-
ion suggested an increase in late events in DES-treated
atients (23), a larger more updated report showed a 50%
eduction in restenosis and similar long-term mortality.
urthermore, there was a significant reduction in MI/death
ithin the first 6 months after DES, which was no longer
ignificant at 4 years (24). Similarly, registries from Canada
nd Denmark have demonstrated that DES were associated
ith reduced TVR with either superior or similar rates of
eath and MI compared with BMS (25,26).
Finally, Settler et al. (27) conducted a meta-analysis of all8 trials (18,023 patients) that prospectively randomizedatients to DES, including trials of primary PCI and
ff-label indications. At 4 years of follow-up, mortality and
he risk of stent thrombosis were similar between DES and
MS. Interestingly, sirolimus-eluting stents were associated
ith a significant reduction in the risk of MI (HR 0.81, 95%
onfidence interval [CI] 0.66 to 0.97; p  0.03) compared
ith BMS, and there was a significant reduction in target
esion revascularization (HR 0.70, 95% CI 0.56 to 0.84; p
.0021). The authors concluded that sirolimus-eluting
tents seemed to be clinically better than either BMS or
aclitaxel-eluting stents.
In summary, although additional trials are warranted, it
ppears that DES are safe and effective both for FDA-
pproved indications as well as for many off-label indica-
ions. Physicians seem to be using their best judgment to use
ff-label DES for lesions at high risk of restenosis, namely,
mall vessels, long lesions, in-stent restenosis, chronic oc-
lusions, or vein grafts. These applications seem very rea-
onable. However, the use of DES for primary PCI remains
ontroversial, with less restenosis benefit, more patient
oncompliance with clopidogrel, and higher risk of stent
alapposition due to size mismatch. Therefore, in my
ractice I avoid DES for primary PCI but use them liberally
n most other patients. Of course, the DES field is always
hanging, and with the wide adoption of prolonged dual
ntiplatelet therapy (28), high pressure inflations for stent
eployment, and increased use of imaging techniques to
ssure stent apposition, we hope that late stent thrombosis
ill no longer be a concern.
eprint requests and correspondence: Dr. Cindy L. Grines,
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. Thirteen Mile Road, Royal Oak, Michigan 48073-6769.
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